Please Wait...

Trident IRT

Rapid Start Up of Complex Studies


DOWNLOAD INFOGRAPHIC

Set up, test, and deploy study protocols within weeks instead of months with Trident — a parameter-driven Interactive Response Technology (IRT) solution. Because the programming is already done, little or no system development effort is required. In fact, Trident reduces the average set up time 50 to 75 percent compared to IRT systems built from the ground up for each new study.

Rapid configuration combined with robust functionality make Trident the IRT of choice for fast launch of complex clinical studies. Built-in alerts and notifications provide proactive tools that help bridge the gap between sites and supply chain management. Adaptive study design, temperature controlled supply management, and drug accountability are standard features. Additionally, a unique set of high-performance capabilities make Trident a best-in-class IRT for the most demanding studies.

Trident IRT provides the ideal solution for the following:

Subject Randomization

Randomizing study subjects into treatment arms for clinical trials can be a difficult and complex undertaking. Study subject bias can be introduced during randomization. Increasingly complex study designs and treatment scenarios complicate the process. Trident simplifies randomization and minimizes study subject allocation bias using proven statistical methods.

Additionally, Trident IRT:

  • Re-randomizes subjects into another treatment arm for another study phase.
  • Randomizes another study subject into a treatment group to replace dropped participants without disrupting study balance.
  • Supports extension studies, rolling over qualified subjects from one study to another.

Drug Tracking, Dispensing and Reconciliation

Trident is tailored to visit-specific strata, making it easy to manage complex dosing scenarios. Because it is configurable for predictive re-supply based on actual demand, Trident eliminates drug supply over-stocks and stock-outs. Additional value-added features include:

  • A controlled substance inventory management tool provides tracking and monitoring to the pill level. Set customizable site inventory limit controls, shipment restrictions, and threshold alerts. Track medication status along the entire supply chain and know whether it was taken, disposed, lost, destroyed, or returned.
  • Drug pooling functionality minimizes drug waste and eliminates unnecessary labeling costs.
  • Combine Trident and Optimizer, Bioclinica's advanced supplies simulation and forecasting tool, for a global supply management solution. Manage clinical supplies based on actual usage and forecasting consumption to significantly minimize waste and reduce costs.

User Requirement Specifications

While the Trident User Requirements Specification is short and simplified, it is fully comprehensive and designed to enable Bioclinica to define the study and match all of your parameters.

This creates a smooth process that helps eliminate errors, misunderstandings, and unwelcome surprises. Built precisely to your specifications, Trident is an easy to validate IRT. Since voice and web components are integrated, there is only one system setup.

Intuitive User Experience

Trident is the intuitive, easy to use IRT designed for the way users actually work. Trident maximizes user productivity and minimizes frustration. Clean screen layout and straightforward navigation guide users to complete tasks in logical progression. Users appreciate the ability to correct data entry errors and print reports when needed. Sites find it especially useful to access reports on their dashboard. System performance is fast and flexible and multiple languages are supported. Since it is so easy to use, training is brief — less than an hour.

Contact us to take Trident IRT for a test drive and see why Bioclinica's global customers use it for the most complicated study scenarios.

Trident IRT Resources

White Papers

Feasibility of shipping clinical trial drugs directly to patients' homes

Depot-to-patient dispensing is a novel approach to the distribution of study drug that can respond to the subject's clinical needs regardless of whether the visit is conducted at the clinic or via telephone.

Agile IRT: Improving Quality and Efficiency in the Study Build Process

Clinical trials are frequently required to run large numbers of patients through blinding (or masking) processes.

Blogs

With the increasing complexity in protocols and need to increase the cost-effectiveness of studies, your IRT-related decisions play an even greater role in ensuring the most appropriate patient randomization and clinical supply strategies.

The revisions in ICH E6 (R2) – Good Clinical Practice has garnered a lot of attention, not least because of the explicit recommendations for the incorporation of a formal risk analysis when planning and executing trials.

Clinical trials for patients with rare, debilitating diseases who have limited mobility and greater caregiving requirements can be challenging, particularly for clinic visits and medication adherence. But, we like a challenge.

ADDITIONAL RESOURCES

Bioclinica Agile RTSM

Download Overview Sheet

Trident IRT

Download data sheet

Trident IRT Reporting Capabilities

Download Data Sheet

Agile IRT: Improving Quality and Efficiency in the Study Build Process

Download White Paper

Feasibility of shipping clinical trial drugs
directly to patients' homes

Download Case Study

THE AGILE APPROACH TO BIOCLINICA'S TRIDENT IRT.

Download Infographic

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (2 days ago)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (3 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (5 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (5 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (5 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (5 days ago)

Latest Blogs: